Khaled Al-Dahmani1, Syed Mohammad2, Fatima Imran2, Chris Theriault, Steve Doucette3, Deborah Zwicker4, Churn-Ern Yip3, David B Clarke5, Syed Ali Imran3. 1. 1Department of Medicine,Tawam Hospital in affiliation with Johns Hopkins,Al Ain,United Arab Emirates. 2. 2Dalhousie University,Halifax,Nova Scotia,Canada. 3. 3Division of Endocrinology,Department of Medicine,Dalhousie University,Halifax,Nova Scotia,Canada. 4. 4Department of Medicine,Cape Breton Regional Hospital,Sydney,Nova Scotia,Canada. 5. 5Division of Neurosurgery,Dalhousie University,Halifax,Nova Scotia,Canada.
Abstract
BACKGROUND: Sellar masses (SM) are mostly benign growths of pituitary or nonpituitary origin that are increasingly encountered in clinical practice. To date, no comprehensive population-based study has reported the epidemiology of SM from North America. AIM: To determine the epidemiology of SM in the province of Nova Scotia, Canada. METHODS: Data from all pituitary-related referrals within the province were prospectively collected in interlinked computerized registries starting in November 2005. We conducted a retrospective analysis on all patients with SM seen within the province between November 2005 and December 2013. RESULTS: A total of 1107 patients were identified, of which 1005 were alive and residing within the province. The mean age at presentation was 44.6±18 years, with an overall female preponderance (62%) and a population prevalence rate of 0.1%. Of patients with SM, 837 (83%) had pituitary adenomas and 168 (17%) had nonpituitary lesions. The relative prevalence and standardized incidence ratio, respectively, of various SM were: nonfunctioning adenomas (38.4%; 2.34), prolactinomas (34.3%; 2.22), Rathke's cyst (6.5%; 0.5), growth hormone-secreting adenomas (6.5%; 0.3), craniopharyngiomas (4.5%; 0.2), adrenocorticotropic hormone-secreting adenomas (3.8%; 0.2), meningiomas (1.9%), and others (3.9%; 0.21). At presentation, 526 (52.3%) had masses ≥1 cm, 318 (31.6%) at <1 cm, and 11 (1.1%) had functioning pituitary adenomas without discernible tumor, whereas tumor size data were unavailable in 150 (14.9%) patients. The specific pathologies and their most common presenting features were: nonfunctioning adenoma (incidental, headaches, and vision loss), prolactinomas (galactorrhea, menstrual irregularity, and headache), growth hormone-secreting adenomas (enlarging extremities and sweating), adrenocorticotropic hormone-secreting adenoma (easy bruising, muscle wasting, and weight gain) and nonpituitary lesions (incidental, headaches, and vision problems). Secondary hormonal deficiencies were common, ranging from 19.6% to 65.7%; secondary hypogonadism, hypothyroidism, and growth hormone deficiencies constituted the majority of these abnormalities. CONCLUSIONS: This is the largest North American study to date to assess the epidemiology of SM in a large stable population. Given their significant prevalence in the general population, more studies are needed to evaluate the natural history of these masses and to help allocate appropriate resources for their management.
BACKGROUND: Sellar masses (SM) are mostly benign growths of pituitary or nonpituitary origin that are increasingly encountered in clinical practice. To date, no comprehensive population-based study has reported the epidemiology of SM from North America. AIM: To determine the epidemiology of SM in the province of Nova Scotia, Canada. METHODS: Data from all pituitary-related referrals within the province were prospectively collected in interlinked computerized registries starting in November 2005. We conducted a retrospective analysis on all patients with SM seen within the province between November 2005 and December 2013. RESULTS: A total of 1107 patients were identified, of which 1005 were alive and residing within the province. The mean age at presentation was 44.6±18 years, with an overall female preponderance (62%) and a population prevalence rate of 0.1%. Of patients with SM, 837 (83%) had pituitary adenomas and 168 (17%) had nonpituitary lesions. The relative prevalence and standardized incidence ratio, respectively, of various SM were: nonfunctioning adenomas (38.4%; 2.34), prolactinomas (34.3%; 2.22), Rathke's cyst (6.5%; 0.5), growth hormone-secreting adenomas (6.5%; 0.3), craniopharyngiomas (4.5%; 0.2), adrenocorticotropic hormone-secreting adenomas (3.8%; 0.2), meningiomas (1.9%), and others (3.9%; 0.21). At presentation, 526 (52.3%) had masses ≥1 cm, 318 (31.6%) at <1 cm, and 11 (1.1%) had functioning pituitary adenomas without discernible tumor, whereas tumor size data were unavailable in 150 (14.9%) patients. The specific pathologies and their most common presenting features were: nonfunctioning adenoma (incidental, headaches, and vision loss), prolactinomas (galactorrhea, menstrual irregularity, and headache), growth hormone-secreting adenomas (enlarging extremities and sweating), adrenocorticotropic hormone-secreting adenoma (easy bruising, muscle wasting, and weight gain) and nonpituitary lesions (incidental, headaches, and vision problems). Secondary hormonal deficiencies were common, ranging from 19.6% to 65.7%; secondary hypogonadism, hypothyroidism, and growth hormone deficiencies constituted the majority of these abnormalities. CONCLUSIONS: This is the largest North American study to date to assess the epidemiology of SM in a large stable population. Given their significant prevalence in the general population, more studies are needed to evaluate the natural history of these masses and to help allocate appropriate resources for their management.
Authors: Pietro Mortini; Gianluca Nocera; Francesca Roncelli; Marco Losa; Anna Maria Formenti; Andrea Giustina Journal: Rev Endocr Metab Disord Date: 2020-12 Impact factor: 6.514
Authors: M Stojanovic; E Manojlovic-Gacic; S Pekic; T Milojevic; D Miljic; M Doknic; M Nikolic Djurovic; Z Jemuovic; M Petakov Journal: Acta Endocrinol (Buchar) Date: 2019 Apr-Jun Impact factor: 0.877
Authors: Grayson A Herrgott; Karam P Asmaro; Michael Wells; Thais S Sabedot; Tathiane M Malta; Maritza S Mosella; Kevin Nelson; Lisa Scarpace; Jill S Barnholtz-Sloan; Andrew E Sloan; Warren R Selman; Ana C deCarvalho; Laila M Poisson; Abir Mukherjee; Adam M Robin; Ian Y Lee; James Snyder; Tobias Walbert; Mark Rosenblum; Tom Mikkelsen; Arti Bhan; John Craig; Steven Kalkanis; Jack Rock; Houtan Noushmehr; Ana Valeria Castro Journal: Neuro Oncol Date: 2022-07-01 Impact factor: 13.029
Authors: Athanasios Fountas; Shu Teng Chai; John Ayuk; Neil Gittoes; Swarupsinh Chavda; Niki Karavitaki Journal: Endocrinol Diabetes Metab Case Rep Date: 2018-03-28
Authors: Jake J Lee; Zindzi S Thompson; Jay F Piccirillo; Cristine N Klatt-Cromwell; Hilary L P Orlowski; Dorina Kallogjeri; Patrik Pipkorn; John S Schneider Journal: JAMA Otolaryngol Head Neck Surg Date: 2020-07-01 Impact factor: 6.223
Authors: Nadine M Vaninetti; David B Clarke; Deborah A Zwicker; Churn-Ern Yip; Barna Tugwell; Steve Doucette; Chris Theriault; Khaled Aldahmani; Syed Ali Imran Journal: Endocr Connect Date: 2018-04-30 Impact factor: 3.335